Compare BGSF & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | TELA |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 51.2M |
| IPO Year | N/A | 2019 |
| Metric | BGSF | TELA |
|---|---|---|
| Price | $4.46 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.00 | $3.31 |
| AVG Volume (30 Days) | 51.2K | ★ 356.4K |
| Earning Date | 11-07-2025 | 11-13-2025 |
| Dividend Yield | ★ 44.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $263,687,000.00 | $77,055,000.00 |
| Revenue This Year | N/A | $18.39 |
| Revenue Next Year | $3.14 | $15.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.60 | 12.24 |
| 52 Week Low | $2.91 | $0.86 |
| 52 Week High | $8.22 | $3.10 |
| Indicator | BGSF | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 57.57 | 45.98 |
| Support Level | $4.25 | $1.10 |
| Resistance Level | $4.66 | $1.21 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 66.66 | 31.58 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.